002773 康弘药业
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入1,046,479-12.70%4,585,1344,452,6583,957,4603,389,028
减:营业总成本690,571-7.83%3,278,7433,160,1302,807,0682,475,902
    其中:营业成本118,654-5.24%465,415466,463438,409388,035
               财务费用(12,345)-20.30%(52,771)(62,341)(52,353)(44,944)
               资产减值损失----(7,561)(2,778)(231)(4,127)
公允价值变动收益193-120.00%551(1,056)(833)--
投资收益(215)59.85%36,23647,27845,03238,064
    其中:对联营企业和合营企业的投资收益(215)59.85%(647)(336)(207)(748)
营业利润359,269-22.83%1,377,3651,381,3301,261,0681,015,368
利润总额358,512-22.54%1,356,1141,352,5371,233,9171,030,296
减:所得税费用55,309-16.43%210,610175,529202,793164,485
净利润303,203-23.55%1,145,5041,177,0081,031,124865,811
减:非控股权益(4,279)26.11%(17,463)(14,223)(13,642)(30,859)
股东净利润307,482-23.13%1,162,9671,191,2311,044,766896,670

市场价值指针
每股收益 (元) *0.330-23.26%1.2601.3001.1400.980
每股派息 (元) *----0.7000.6000.3800.150
每股净资产 (元) *10.4275.92%10.0939.4088.4887.506
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容